December 18, 2025 landed like one of those industry moments that barely makes noise when it happens, then echoes for years. Manifold closed an $18M Series B led by Reach Capital, with SilverArc Capital and Industry Ventures stepping in and TQ Ventures plus Calibrate Ventures running it back. Total capital raised now sits at $40M. No fireworks, no chest beating, just a clear signal that serious infrastructure still attracts serious conviction when the problem is real and the execution shows receipts.
Manifold was founded in 2016 as an AI lab, back when “vertical AI” was not yet dinner conversation. Vinay Seth Mohta, Vivek Mohta, Sourav Dey, and Rajendra Koppula did not start by chasing buzzwords. They started by staring down biomedical research as it actually exists: fragmented data, heroic spreadsheets, brittle pipelines, and timelines that stretch from weeks into months because the pipes cannot keep up with the science. Their answer was not louder models, but better plumbing.
The platform they built treats life sciences like the high-stakes system it is. Agent OS lets researchers ask real questions in natural language and get real analysis back across omics, imaging, clinical, and longitudinal data. Multimodal data stops living in silos and starts behaving like a system. Governance is designed in, not bolted on. Collaboration works across institutions without anyone giving up data sovereignty. One org unified 11 terabytes across 1.5M patients. Teams that used to wait months now move in minutes. That is not hype velocity. That is operational gravity shifting.
This shows up in who is using the product. Foundation Medicine. Indiana University’s Melvin and Bren Simon Comprehensive Cancer Center. Winship Cancer Institute of Emory University. University of Virginia. Morehouse School of Medicine. The Broad Institute. Tens of thousands of researchers across hundreds of orgs relying on the Terra platform that Manifold now operates. AWS HealthOmics and Amazon Bedrock under the hood. Anthropic Claude for Life Sciences embedded where the work actually happens. This is not AI tourism. This is infrastructure people depend on.
Reach Capital led because category leaders tend to emerge where the mess is hardest. Jennifer Carolan backed a team that understands precision medicine is not a slogan, it is an execution problem. TQ Ventures and Calibrate Ventures returning says the product matched the thesis. SilverArc Capital and Industry Ventures joining says the next chapter is about scale, not survival.
Manifold is not promising miracles or silver bullets. They are selling time back to scientists, trust back to collaboration, and clarity back to data. In a $2T life sciences market buried under complexity, that kind of leverage compounds fast, and once you see it working, it is hard to unsee where the industry is heading.
Startups Startup Funding Venture Capital Series B AI AI Agents Life Sciences Research Healthcare Health Tech Data Data Driven Infrastructure Technology Innovation Tech Ecosystem Startup Ecosystem DC Talks
